NESS ZIONA, Israel, September 30, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today greets its partner, Zhejiang Jingxin Pharmaceutical Co Ltd. To our friends and partners at Jingxin Pharma,...
90% of relapsing remitting multiple sclerosis (RRMS) patients on GA Depot demonstrated no evidence of disease activity (NEDA) at four years Data suggest that GA Depot may also have potential as a primary progressive multiple sclerosis (PPMS) treatment NESS...
Mylan to invest an additional $20M in Mapi Pharma in support of continued progress on Phase 3 clinical studies NESS ZIONA, Israel, June 15, 2020 — Mapi Pharma Ltd., a privately held, fully integrated, late clinical stage biopharmaceutical company today announced...
Ness Ziona, Israel, October 28, 2019 — Mapi Pharma Ltd. announced today that the first patient has been enrolled in its Phase III study with GA Depot for relapsing forms of multiple sclerosis (RMS). Glatiramer acetate, the active material of Copaxone®, or...
Results for Glatiramer Acetate (GA) Depot 3 year analysis in RRMS, GA Depot safety results in RRMS and PPMS, and novel anti-BMP for remyelination will be presented ECTRIMS 2019 to be held in Stockholm, Sweden on September 11-13 NESS ZIONA, Israel – September 4,...
Sterile injectable facility will enable the supply of commercial needs as part of the agreement with Mylan NESS ZIONA, Israel – July 15, 2019 – Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company announced today that is has... 